Sight Sciences, Inc. Common Stock
SGHTSight Sciences, Inc. (SGHT) is a medical technology company focused on developing innovative devices and solutions for treating eye conditions, particularly those related to the anterior segment, such as glaucoma and other ocular diseases. The company's products aim to improve patient outcomes through minimally invasive procedures and advanced ocular diagnostics.
Company News
UnitedHealthcare updated its Glaucoma Surgical Treatments policy to cover OMNI Surgical System procedures for treating mild to moderate open-angle glaucoma, effective October 1, 2025, covering approximately 30 million lives.
A cost-utility analysis revealed that TearCareĀ® System offers cost savings and better health utility compared to cyclosporine 0.05% for treating meibomian gland disease-associated dry eye disease, with $903 annual per-patient savings.
Sight Sciences published 24-month results of the SAHARA clinical trial demonstrating the durability of the TearCareĀ® System for treating dry eye disease, showing statistically significant improvements in patient symptoms and eye health metrics through two annual treatments.
The global dry eye treatment devices market is expected to reach $898.78 million by 2033, driven by the increasing prevalence of dry eye disease and the development of innovative treatment options. The market is seeing a shift towards more sophisticated devices that offer targeted therapies, such as the LipiFlow System and iLux Device for treatin...
Sight Sciences, Inc. (Nasdaq: SGHT) announced that it will report its financial results for the second quarter of 2024 on August 1, 2024. The company will host a conference call to discuss the results.
